Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
Authors:
- D. MilesDMD. Miles
- A. ChanACA. Chan
- G. RomieuGRG. Romieu
- L. Y. DirixLDL. Y. Dirix
- J. CortesJCJ. Cortes
- X. PivotXPX. Pivot
- P. TomczakPTP. Tomczak
- T. TaranTTT. Taran
- N. HarbeckNHN. Harbeck
- G. G. StegerGSG. G. Steger
- 20 May 2008
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , LBA1011